Skip to main content
SpringerLink
Log in

Acute Kidney Injury in the Cirrhotic Patient: Unique Features and Challenges

  • Management of the Cirrhotic Patient (A Cardenas and N Reau, Section Editors)
  • Published:
Current Hepatology Reports Aims and scope Submit manuscript

Abstract

Acute kidney injury (AKI) is a frequent complication in patients with cirrhosis which is associated with significant mortality and morbidity in these patients. AKI has been recently defined either by an increase in serum creatinine (sCr) of more than 0.3 mg/dl (≥26.5 μmol/l) within 48 h or by a percentage increase in sCr of more than 50 % from the baseline, which is known, or presumed, to have occurred within the previous 7 days. The main advantage of this new definition for AKI is the sensitivity in identifying patients in the very early stage of AKI by small incremental changes in sCr allowing institution of appropriate treatment and preventing progression. This article details the unique features of AKI in patients with cirrhosis, the challenges in the diagnosis prognosis and management of AKI, and the outcomes of different forms of AKI including the potential role of novel biomarkers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology. 2003;37(2):233–43.

    Article  PubMed  Google Scholar 

  2. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology. 2008;48(6):2064–77.

    Article  CAS  PubMed  Google Scholar 

  3. Belcher JM, Parikh CR, Garcia-Tsao G. Acute kidney injury in patients with cirrhosis: perils and promise. Clin Gastroenterol Hepatol. 2013;11(12):1550–8.

    Article  CAS  PubMed  Google Scholar 

  4. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996;23(1):164–76.

    Article  CAS  PubMed  Google Scholar 

  5. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis: a consensus workshop of the international ascites club. Gut. 2007;56(9):1310–8.

    PubMed Central  CAS  PubMed  Google Scholar 

  6. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Belcher JM, Garcia-Tsao G, Sanyal AJ, Bhogal H, Lim JK, Ansari N, et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology. 2013;57(2):753–62.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Piano S, Rosi S, Maresio G, Fasolato S, Cavallin M, Romano A, et al. Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol. 2013;59(3):482–9. In this large cohort study in hospitalized patients with cirrhosis it was shown that addition of either the progression of AKIN stage or the cut-off of sCr ≥ 1.5mg/dl to the AKIN criteria improves its prognostic accuracy.

    Article  PubMed  Google Scholar 

  9. Fagundes C, Barreto R, Guevara M, Garcia E, Solà E, Rodríguez E, et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol. 2013;59(3):474–81. Large prospective cohort study which showed that classification that combines the AKIN criteria and cut-off serum sCr of 1.5mg/dl of kidney failure in cirrhosis provides a better risk stratification than AKIN criteria alone.

    Article  PubMed  Google Scholar 

  10. Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut. 2013;62(1):131–7.

    Article  PubMed  Google Scholar 

  11. de Carvalho JR, Villela-Nogueira CA, Luiz RR, Guzzo PL, da Silva Rosa JM, Rocha E, et al. Acute kidney injury network criteria as a predictor of hospital mortality in cirrhotic patients with ascites. J Clin Gastroenterol. 2012;46(3):e21–6.

    Article  PubMed  Google Scholar 

  12. Wong F, O’Leary JG, Reddy KR, Patton H, Kamath PS, Fallon MB, et al. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology. 2013;145(6):1280–8.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Altamirano J, Fagundes C, Dominguez M, García E, Michelena J, Cárdenas A, et al. Acute kidney injury is an early predictor of mortality for patients with severe alocholic hepatitis. R. Acute kidney injury is an early predictor of mortality for patients withalcoholic hepatitis. Clin Gastroenterol Hepatol. 2012;10(1):65–71.

    Article  PubMed  Google Scholar 

  14. Bellomo R, Ronco C, Kellum J, Mehta RL, Palevsky P, et al. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204–12.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Kellum JA, Lameire N, KDIGO AKI. Guideline Work Group. Diagnosis, evaluation and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17(1):204.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes A, et al. Working party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut. 2010;60(5):702–9.

    Article  Google Scholar 

  17. Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. International Club of Ascites. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015;64(4):531–7. Revised consensus for diagnosis and management of AKI including AKI-HRS for patients with cirrhosis by ICA.

    Article  CAS  PubMed  Google Scholar 

  18. Angeli P, Ginès P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62(4):968–74. Revised consensus for diagnosis and management of AKI including AKI-HRS for patients with cirrhosis by ICA.

    Article  PubMed  Google Scholar 

  19. Lolekha PH, Jaruthunyaluck S, Srisawasdi P. Deproteinization of serum: another best approach to eliminate all forms of bilirubin interference on sCr by the kinetic Jaffe reaction. J Clin Lab Anal. 2001;15(3):116–21.

    Article  CAS  PubMed  Google Scholar 

  20. Wong F, O’Leary JG, Reddy KR, Kamath PS, Garcia-Tsao G, Maliakkal B, et al. A cut-off sCr value of 1.5 mg/dl for AKI -To be or not to be. J Hepatol. 2015;62(3):741–3.

    Article  PubMed  Google Scholar 

  21. Thalheimer U, Burroughs AK. To close the stable door before the horse has bolted. J Hepatol. 2014;60(3):678–9.

    Article  PubMed  Google Scholar 

  22. Rosi S, Piano S, Frigo AC, Morando F, Fasolato S, Cavallin M, et al. New ICA criteria for the diagnosis of acute kidney injury in cirrhotic patients: can we use an imputed value of serum creatinine? Liver Int. 2015;35(9):2108–14.

    Article  CAS  PubMed  Google Scholar 

  23. Trawalé JM, Paradis V, Rautou PE, Francoz C, Escolano S, Sallée M, et al. The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int. 2010;30(5):725–32.

    Article  PubMed  Google Scholar 

  24. Wadei HM, Geiger XJ, Cortese C, Mai ML, Kramer DJ, Rosser BG, et al. Kidney allocation to liver transplant candidates with renal failure of undetermined etiology: role of percutaneous renal biopsy. Am J Transplant. 2008;8(12):2618–26.

    Article  CAS  PubMed  Google Scholar 

  25. Calmus Y, Conti F, Cluzel P, Hill G, Antoine C, Scatton O, et al. Prospective assessment of renal histopathological lesions in patients with end-stage liver disease: effects on long-term renal function after liver transplantation. J Hepatol. 2012;57(3):572–6.

    Article  PubMed  Google Scholar 

  26. Betjes MG, Bajema I. The pathology of jaundice-related renal insufficiency: cholemic nephrosis revisited. J Nephrol. 2006;19(2):229–33.

    CAS  PubMed  Google Scholar 

  27. Angeli P, Tonon M, Pilutti C, Morando F, Piano S. Sepsis-induced acute kidney injury in patients with cirrhosis. Hepatol Int. 2015

  28. Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015. doi:10.1016/j.jhep.2015.07.004.

    Google Scholar 

  29. Leone M, Moreau R. Leukocyte Toll-like receptor 2-mitochondria axis in sepsis: unraveling immune response sophistication. Anesthesiology. 2014;121(6):1147–9.

    Article  PubMed  Google Scholar 

  30. Barreto R, Fagundes C, Guevara M, Solà E, Pereira G, Rodríguez E, et al. Type-1 hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, and survival. Hepatology. 2014;59(4):1505–13.

    Article  PubMed  Google Scholar 

  31. Rodríguez E, Elia C, Solà E, Barreto R, Graupera I, Andrealli A, et al. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. J Hepatol. 2014;60(5):955–61.

    Article  PubMed  Google Scholar 

  32. Francoz C, Durand F. Type-1 hepatorenal syndrome in patients with cirrhosis and infection vs. sepsis-induced acute kidney injury: What matters? J Hepatol. 2014;60(5):907–9.

    Article  PubMed  Google Scholar 

  33. Shah N, Mohamed FE, Jover-Cobos M, Macnaughtan J, Davies N, Moreau R, et al. Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis. Liver Int. 2013;33:398–409. This study provides proof of concept that renal dysfunction in patients with cirrhosis with superimposed inflammation is associated with tubular injury and apoptosis highlighting a different pathophysiological basis.

    Article  CAS  PubMed  Google Scholar 

  34. Shah N, Dhar D, El Zahraa MF, Habtesion A, Davies NA, Jover-Cobos M, et al. Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression. J Hepatol. 2012;56(5):1047–53.

    Article  CAS  PubMed  Google Scholar 

  35. Wong BT, Chan MJ, Glassford NJ, Mårtensson J, Bion V, Chai SY, et al. (2015) Mean arterial pressure and mean perfusion pressure deficit in septic acute kidney injury. J Crit Care.

  36. Angeli P, Morando F, Cavallin M, Piano S. Hepatorenal syndrome. Contrib Nephrol. 2011;174:46–55.

    Article  PubMed  Google Scholar 

  37. Esson ML, Schrier RW. Diagnosis and treatment of acute tubular necrosis. Ann Intern Med. 2002;137(9):744–52.

    Article  PubMed  Google Scholar 

  38. Martín-Llahí M, Guevara M, Torre A, Fagundes C, Restuccia T, Gilabert R, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology. 2011;140(2):488–96.

    Article  PubMed  Google Scholar 

  39. Slack AJ, McPhail MJ, Ostermann M, Bruce M, Sherwood R, Musto R, et al. Predicting the development of acute kidney injury in liver cirrhosis—an analysis of glomerular filtration rate, proteinuria and kidney injury biomarkers. Aliment Pharmacol Ther. 2013;37(10):989–97.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Séronie-Vivien S, Delanaye P, Piéroni L, Mariat C, Froissart M, Cristol JP, et al. SFBC “Biology of renal function and renal failure” working group. Cystatin C current position and future prospects. Clin Chem Lab Med. 2008;46(12):1664–86.

    Article  PubMed  Google Scholar 

  41. Tsigou E, Psallida V, Demponeras C, Boutzouka E, Baltopoulos G. Role of new biomarkers: functional and structural damage. Crit Care Res Pract. 2013;2013:361078.

    PubMed Central  PubMed  Google Scholar 

  42. Conti M, Moutereau S, Zater M, et al. Urinary cystatin C as a specific marker of tubular dysfunction, clinical chemistry and laboratory medicine. Clin Chem Lab Med. 2006;44(3):288–91.

    Article  CAS  PubMed  Google Scholar 

  43. De Souza V, Hadj-Aissa A, Dolomanova O, Rabilloud M, Rognant N, Lemoine S, et al. Creatinine- versus cystatine C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis. Hepatology. 2014;59(4):1522–31.

    Article  PubMed  Google Scholar 

  44. Allen AM, Kim WR, Larson JJ, Colby C, Therneau TM, Rule AD. Serum cystatin c as an indicator of renal function and mortality in liver transplant recipients. Transplantation. 2015;99(7):1431–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Mindikoglu AL, Dowling TC, Weir MR, Seliger SL, Christenson RH, Magder LS, et al. Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. Hepatology. 2014;59(4):1532–42.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Wan ZH, Wang JJ, You SL, Liu HL, Zhu B, Zang H, et al. Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure. World J Gastroenterol. 2013;19(48):9432–8.

    Article  PubMed Central  PubMed  Google Scholar 

  47. Belcher JM, Sanyal AJ, Garcia-Tsao G, Ansari N, Coca SG, Shlipak MG, et al. Early trends in cystatin C and outcomes in patients with cirrhosis and acute kidney injury. Int J Nephrol. 2014;2014:708585.

    Article  PubMed Central  PubMed  Google Scholar 

  48. Ichimura T, Bonventre JV, Bailly V, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells ater injury. J Biol Chem. 1998;273(7):4135–42.

    Article  CAS  PubMed  Google Scholar 

  49. Wang G, Gong Y, Anderson J, Sun D, Minuk G, Roberts MS, et al. Antioxidative function of L-FABP in L-FABP stably transfected Chang liver cells. Hepatology. 2005;42(4):871–9.

    Article  CAS  PubMed  Google Scholar 

  50. Ek-Von Mentzer BA, Zhang F, Hamilton JA. Binding of 13-HODE and 15-HETE to phospholipid bilayers, albumin, and intracellular fatty acid binding proteins.implications for transmembrane and intracellular transport and for protection from lipid peroxidation. J Biol Chem. 2001;276(19):15575–80.

    Article  CAS  PubMed  Google Scholar 

  51. Edelstein CL, Hoke TS, Somerset H, Fang W, Klein CL, Dinarello CA, et al. Proximal tubules from caspase-1-deficient mice are protected againsthypoxia-induced membrane injury. Nephrol Dial Transplant. 2007;22(4):1052–61.

    Article  CAS  PubMed  Google Scholar 

  52. Flower DR. Experimentally determined lipocalin structures. Biochim Biophys Acta. 2000;1482(1–2):46–56.

    Article  CAS  PubMed  Google Scholar 

  53. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature. 2004;432(7019):917–21.

    Article  CAS  PubMed  Google Scholar 

  54. Belcher JM, Sanyal AJ, Peixoto AJ, Perazella MA, Lim J. Thiessen et al. TRIBE-AKI Consortium. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology. 2014;60(2):622–32. The study evaluates a panel of biomarkers for the differential diagnosis of AKI.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  55. Fagundes C, Pepin MN, Guevara M, et al. Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol. 2012;57(2):267–73.

    Article  CAS  PubMed  Google Scholar 

  56. Barreto R, Elia C, Solà E, Moreira R, Ariza X, Rodríguez E, et al. Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. J Hepatol. 2014;61(1):35–42.

    Article  CAS  PubMed  Google Scholar 

  57. Ariza X, Solà E, Elia C, Barreto R, Moreira R, Morales-Ruiz M, et al. Analysis of a urinary biomarker panel for clinical outcomes assessment in cirrhosis. PLoS One. 2015;10(6):e0128145.

    Article  PubMed Central  PubMed  Google Scholar 

  58. Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol. 2008;103(7):1689–97.

    Article  CAS  PubMed  Google Scholar 

  59. Nassar Junior AP, Farias AQ, D’Albuquerque LA, et al. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One. 2014;9:e107466. The only meta-analysis of 4 studies which compares terlipressin and noradrenaline for management of HRS.

    Article  PubMed Central  PubMed  Google Scholar 

  60. Cavallin M, Kamath PS, Merli M, for the Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology. 2015;62(2):567–74. RCT which for the first time shows octreotide-midodrine inferior to terlipressin for treatment of HRS.

    Article  CAS  PubMed  Google Scholar 

  61. Gerbes AL, Huber E, Gülberg V, et al. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration. Gastroenterology. 2009;137(3):1179.

    Article  PubMed  Google Scholar 

  62. Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Terlipressin Study Group. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of sCr to hemodynamics. J Hepatol. 2011;55(2):315–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  63. Simpson N, Cho YW, Cicciarelli JC, Selby RR, Fong TL, et al. Comparison of renal allograft outcomes in combined liver-kidney transplantation versus subsequent kidney transplantation in liver transplant recipients: analysis of UNOS database. Transplantation. 2006;82(10):1298–303.

    Article  PubMed  Google Scholar 

  64. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type1 hepatorenal syndrome. Gastroenterology. 2008;134(5):1360–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  65. Ikegami T, Shirabe K, Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, et al. The impact of renal replacement therapy before or after living donor liver transplantation. Clin Transpl. 2012;26(1):143–8.

    Article  Google Scholar 

  66. Xing T, Zhong L, Chen D, Peng Z. Experience of combined liver-kidney transplantation for acute-on-chronic liver failure patients with renal dysfunction. Transplant Proc. 2013;45(6):2307–13.

    Article  CAS  PubMed  Google Scholar 

  67. Northup PG, Argo CK, Bakhru MR, et al. Pretransplant predictors of recovery of renal function after liver transplantation. Liver Transpl. 2010;16(4):440–6.

    PubMed  Google Scholar 

  68. Bajaj JS, O’Leary JG, Reddy KR, Wong F, Olson JC, Subramanian RM, et al. Kamath PS; NACSELD. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology. 2012;56(6):2328–35.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  69. Kribben A, Gerken G, Haag S, Herget-Rosenthal S, Treichel U, Betz C, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology. 2012;142(4):782–9.

    Article  CAS  PubMed  Google Scholar 

  70. Bañares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology. 2013;57(3):1153–62.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hepatology, Institute of Liver and Biliary Science, New Delhi, India

    Rakhi Maiwall

  2. Inserm, U1149, Centre de Recherche sur l’Inflammation (CRI), Clichy and Paris, France

    Richard Moreau

  3. UMRS1149, Université Paris Diderot-Paris 7, Paris, France

    Richard Moreau

  4. Département Hospitalo-Universitaire (DHU) UNITY, Service d’Hépatologie, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy, France

    Richard Moreau

  5. Laboratoire d’Excellence Inflamex, ComUE Sorbonne Paris Cité, Paris, France

    Richard Moreau

Authors
  1. Rakhi Maiwall
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Moreau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Moreau.

Ethics declarations

Conflict of Interest

Rakhi Maiwall and Richard Moreau declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Management of the Cirrhotic Patient

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maiwall, R., Moreau, R. Acute Kidney Injury in the Cirrhotic Patient: Unique Features and Challenges. Curr Hepatology Rep 15, 26–35 (2016). https://doi.org/10.1007/s11901-016-0290-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-016-0290-1

Keywords

Search

Navigation